vs
Side-by-side financial comparison of SOLENO THERAPEUTICS INC (SLNO) and Viridian Therapeutics, Inc.\DE (VRDN). Click either name above to swap in a different company.
Viridian Therapeutics, Inc.\DE is the larger business by last-quarter revenue ($70.6M vs $66.0M, roughly 1.1× SOLENO THERAPEUTICS INC). SOLENO THERAPEUTICS INC runs the higher net margin — 39.4% vs -49.0%, a 88.4% gap on every dollar of revenue. SOLENO THERAPEUTICS INC produced more free cash flow last quarter ($43.5M vs $-84.7M).
SOLENO THERAPEUTICS INC is a clinical-stage biopharmaceutical company specializing in developing novel therapies for rare endocrine, metabolic, and neurodevelopmental disorders. Its lead product candidate targets Prader-Willi syndrome, a rare genetic condition, with key patient markets across North America and the European Union.
Viridian Therapeutics is a clinical-stage biotechnology firm developing novel disease-modifying therapies for rare, serious autoimmune and inflammatory diseases. Its lead pipeline candidate targets thyroid eye disease, a debilitating orbital disorder, with primary market focus on North America and Europe.
SLNO vs VRDN — Head-to-Head
Income Statement — Q3 FY2025 vs Q3 FY2025
| Metric | | |
|---|---|---|
| Revenue | $66.0M | $70.6M |
| Net Profit | $26.0M | $-34.6M |
| Gross Margin | 98.3% | — |
| Operating Margin | 33.5% | -56.7% |
| Net Margin | 39.4% | -49.0% |
| Revenue YoY | — | 81958.1% |
| Net Profit YoY | 134.0% | 54.9% |
| EPS (diluted) | $0.47 | — |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q3 25 | $66.0M | $70.6M | ||
| Q2 25 | $32.7M | — |
| Q3 25 | $26.0M | $-34.6M | ||
| Q2 25 | $-4.7M | — |
| Q3 25 | 98.3% | — | ||
| Q2 25 | 97.9% | — |
| Q3 25 | 33.5% | -56.7% | ||
| Q2 25 | -20.0% | — |
| Q3 25 | 39.4% | -49.0% | ||
| Q2 25 | -14.4% | — |
| Q3 25 | $0.47 | — | ||
| Q2 25 | $-0.09 | — |
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest quarter.
| Metric | | |
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | $498.9M | $490.9M |
| Total DebtLower is stronger | — | — |
| Stockholders' EquityBook value | $494.8M | $503.0M |
| Total Assets | $599.9M | $577.1M |
| Debt / EquityLower = less leverage | — | — |
8-quarter trend — quarters aligned by calendar period.
| Q3 25 | $498.9M | $490.9M | ||
| Q2 25 | $286.8M | — |
| Q3 25 | $494.8M | $503.0M | ||
| Q2 25 | $240.1M | — |
| Q3 25 | $599.9M | $577.1M | ||
| Q2 25 | $332.3M | — |
Cash Flow & Capital Efficiency
How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.
| Metric | | |
|---|---|---|
| Operating Cash FlowLast quarter | $43.5M | $-84.6M |
| Free Cash FlowOCF − Capex | $43.5M | $-84.7M |
| FCF MarginFCF / Revenue | 65.8% | -120.1% |
| Capex IntensityCapex / Revenue | 0.0% | 0.2% |
| Cash ConversionOCF / Net Profit | 1.67× | — |
| TTM Free Cash FlowTrailing 4 quarters | — | — |
8-quarter trend — quarters aligned by calendar period.
| Q3 25 | $43.5M | $-84.6M | ||
| Q2 25 | $-12.6M | — |
| Q3 25 | $43.5M | $-84.7M | ||
| Q2 25 | $-12.6M | — |
| Q3 25 | 65.8% | -120.1% | ||
| Q2 25 | -38.6% | — |
| Q3 25 | 0.0% | 0.2% | ||
| Q2 25 | 0.0% | — |
| Q3 25 | 1.67× | — | ||
| Q2 25 | — | — |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
